- AngioDynamics Inc (NASDAQ: ANGO) has reported a Q1 FY23 adjusted EPS loss of $(0.06), missing the consensus EPS of $0.02 and lower than $(0.02) a year ago.
- Q1 sales increased 5.9% Y/Y to $81.5 million, missing the analyst consensus of $83.42 million.
- Med Tech's net sales were $22.8 million, up 29.6%, driven by Auryon sales and NanoKnife disposable sales.
- Med Device net sales were $58.7 million, a decline of 1.1% compared to the prior-year period.
- The gross margin compressed 20 bps to 51.9%, impacted by macro forces, including labor shortages and increased costs for labor, raw materials, and freight.
- Adjusted EBITDA was $3 million, compared to $3.6 million a year ago.
- Guidance: For FY23, AngioDynamics reaffirms sales of $342- $348 million versus the consensus of $344.21 million.
- The company expects a gross margin of approximately 52.5% - 54.5% and adjusted EPS of $0.01 - $0.06 (consensus of $0.02).
- Price Action: ANGO shares are down 13.02% at $18.75 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
